Spectrum Pharmaceuticals - Chancen und Risiken? (Seite 117)
eröffnet am 31.08.08 11:55:05 von
neuester Beitrag 10.08.23 11:06:43 von
neuester Beitrag 10.08.23 11:06:43 von
Beiträge: 4.229
ID: 1.143.896
ID: 1.143.896
Aufrufe heute: 4
Gesamt: 285.568
Gesamt: 285.568
Aktive User: 0
ISIN: US84763A1088 · WKN: 164623 · Symbol: SPPI
1,0300
USD
0,00 %
0,0000 USD
Letzter Kurs 01.08.23 Nasdaq
Neuigkeiten
| TitelBeiträge |
|---|
20.07.23 · Business Wire (engl.)  |
30.06.23 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,5800 | +54,90 | |
| 24,500 | +22,50 | |
| 0,7000 | +16,67 | |
| 2,0400 | +16,50 | |
| 1,9380 | +16,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 160,90 | -14,14 | |
| 16,100 | -15,26 | |
| 4,0000 | -20,00 | |
| 0,7500 | -35,34 | |
| 2,1000 | -47,50 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 41.729.598 von Magnetfeldfredy am 01.07.11 14:15:15Ein Blogger-Artikel halt. Könnte jeder schreiben, du und ich.
Einiges hst er auch falsch. Cash ist z.B. nicht 141 Mio USD, sondern unter 100Mio USD. Raj hat in Q2 den Trick aufgefahren, dass er nicht mehr den Cash nennt, sondern Cash, Investment und Receivables. Das sieht in der Betragssumme natürlich weit höher aus.
Wichtig sind in Q3 die Q2-Zahlen und die CUP Daten von Belinostat.
Einiges hst er auch falsch. Cash ist z.B. nicht 141 Mio USD, sondern unter 100Mio USD. Raj hat in Q2 den Trick aufgefahren, dass er nicht mehr den Cash nennt, sondern Cash, Investment und Receivables. Das sieht in der Betragssumme natürlich weit höher aus.
Wichtig sind in Q3 die Q2-Zahlen und die CUP Daten von Belinostat.
Antwort auf Beitrag Nr.: 41.681.863 von VaJo am 22.06.11 10:12:38Nicht schlecht:
Spectrum Pharmaceuticals: a short story
Those shorting a small, thriving biotech company called Spectrum Pharmaceuticals face an unhappy ending.
30 June 11 21:09, Shlomi Cohen
In recent months, a mini drama has been taking place on Wall Street, involving the managers of a small, prosperous biotechnology company called Spectrum Pharmaceuticals (SPPI), which I am considering bringing into the portfolio I manage here soon, and the short players that have latched onto it. Other cast members are a journalist, over-zealous to my mind, on thestreet.com, and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA), as an unwilling bit player.
Spectrum is run by a well-known figure in the US biotechnology world, Dr. Rajesh Shrotriya (67). His philosophy is that a small company should not develop drugs from scratch, because the costs are huge, but should focus on buying rights to drugs that are at advanced stages of development, and have been abandoned for one reason of another.
Spectrum currently sells two life-extending treatments for colorectal cancer and lymphoma, and it has in its pipeline two more drugs at advanced stages of development, and with large potential.
The company has a low market cap, of $430 million, even though its financial numbers are excellent, the kind one does not often find in small biotech companies of this type. At the end of March, it had $141 million dollars cash, with no debt. First quarter sales totaled $44 million, representing four-fold year-on-year growth, and it made a profit in the quarter of $13 million, or $0.25 per share, despite the high costs of two drugs still undergoing trials. Analysts project sales of at least $130 million this year, compared with just $61 million in 2010, and half that in 2009.
Most of the sales in the past year have come from colorectal cancer treatment Fusilev, which the company sells in the US, but Teva has a similar, and cheaper, generic injection, and so in the past year the short players have turned their attention to Spectrum, on the assumption that it has no chance against Teva. They ramped up the short position to an annual record of 7 million shares, while the share price rose from a rock-bottom $4 to over $10 at the end of April, just before the FDA meeting to decide whether to approve expanded use of Fuzilev.
Spectrum's share price has jumped in the past year, among other things because contamination was discovered at the Teva plant in the US that produces the generic injection, leading to a temporary shutdown, and a shortage that boosted Spectrum's sales. The short players built their position against the stock on the basis of two assumptions. The first, and more important of the two, was that on April 29, the FDA would not allow expanded use of Fusilev, as had happened a year earlier, sending the stock tumbling. The second was that Teva's plant was due to resume production, and so sales of Spectrum's Fusilev would drop, being similar to but costlier than Teva's.
Thestreet.com biotech reporter Adam Feuerstein had taken a position against investing in Spectrum all year, which made investors suspect him of being connected to the hedge funds that were shorting the stock. The climax came on Monday, May 2, after Spectrum announced that it had obtained the FDA approval for expanding use of the Fusilev injection to advanced metastatic colorectal cancer patients, and that it was gearing up to boost production at the FDA's request, because of the shortage brought about by the continued closure of the Teva plant.
On the back of the positive announcement, Spectrum's share price opened with a 14% leap on May 2, to a record $10.3, but in the course of the session, when the momentum was at its peak, Feuerstein published an article on thestreet.com against the company, claiming that the approval was worthless, since Teva would resume production at any moment, and its injection was similar but cheaper. The damage was done. The stock changed direction and headed south, tumbling to almost $7 within two weeks, and the strong first quarter results released two days after the article was published failed to help.
On their blogs, investors went crazy at the precise timing of Feuerstein's article, at the stock's intraday peak, which, they claimed, played quite fantastically to the short players' benefit. On his personal blog, Feuerstein denies having anything against the company or its CEO, claiming him as old friend. Despite that, he renewed the attack last week, but this time Shrotriya was armed and ready, with ammunition that prevented the stock from collapsing.
The zealous Feuerstein discovered that Teva had reported on a professional website that although the US plant was still being tested, and was not producing in large quantities, at the request of the FDA, which feared a shortage, it was importing large consignments of the injection into the US from Europe. On the basis of that discovery, he came out with another negative article, claiming that Spectrum would be hurt by Teva's imports, and that its advantage was at an end. On a normal day, that would have been enough to undermine the share, but it seems that Shrotriya also saw Teva's report, and knew who would use it against him.
Spectrum anticipated with an announcement of its own, at the end of which it stated that "We expect record second quarter and full-year 2011 revenues." The announcement said, "We are now able to meet the growing needs of the tens of thousands of patients who depend upon FUSILEV's availability. Having multiple US suppliers also reduces the risk of supply interruptions, so physicians who prefer to use FUSILEV in their treatment regimens do not have to seek alternative treatment options," a hint at Teva. Incidentally, as far as Teva is concerned, this is something negligible relative to its sales, and there are those who say that Teva has no interest in promoting its drug, because of its low profitability, but that the company is acting under pressure from the FDA, which fears a shortage.
The point is that I see Spectrum as an attractive stock for anyone looking for a big biotech dream that could come true through the two new drugs it has in development, and that are slated to be submitted for FDA approval next year. They are aimed at very large markets in oncology. But until then, the financial risk is very low, because the company has lots of cash, which is not typical of small companies, and what is more it has the two drugs that are already selling and earning profits, and it is not at all clear how much of a threat Teva really presents to the colorectal cancer treatment.
In my view, this being the case, sooner or later the large short position will lead to the short players being wiped out, which in turn will make the share price soar. In addition, Spectrum's CEO does not deny that the company is a potential takeover target for one of the pharmaceutical giants, and so he has taken care to arrange a bonus for himself if the sale is at a valuation above $750 million, a bonus that will also be paid if the company reaches that market cap without a sale, through a normal rise in the share price thanks to business growth.
Published by Globes [online], Israel business news - www.globes-online.com - on June 30, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
בנוסף אולי יעניין אותך לנסוע במציאות בעולמו של וולט דיסני
Spectrum Pharmaceuticals: a short story
Those shorting a small, thriving biotech company called Spectrum Pharmaceuticals face an unhappy ending.
30 June 11 21:09, Shlomi Cohen
In recent months, a mini drama has been taking place on Wall Street, involving the managers of a small, prosperous biotechnology company called Spectrum Pharmaceuticals (SPPI), which I am considering bringing into the portfolio I manage here soon, and the short players that have latched onto it. Other cast members are a journalist, over-zealous to my mind, on thestreet.com, and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA), as an unwilling bit player.
Spectrum is run by a well-known figure in the US biotechnology world, Dr. Rajesh Shrotriya (67). His philosophy is that a small company should not develop drugs from scratch, because the costs are huge, but should focus on buying rights to drugs that are at advanced stages of development, and have been abandoned for one reason of another.
Spectrum currently sells two life-extending treatments for colorectal cancer and lymphoma, and it has in its pipeline two more drugs at advanced stages of development, and with large potential.
The company has a low market cap, of $430 million, even though its financial numbers are excellent, the kind one does not often find in small biotech companies of this type. At the end of March, it had $141 million dollars cash, with no debt. First quarter sales totaled $44 million, representing four-fold year-on-year growth, and it made a profit in the quarter of $13 million, or $0.25 per share, despite the high costs of two drugs still undergoing trials. Analysts project sales of at least $130 million this year, compared with just $61 million in 2010, and half that in 2009.
Most of the sales in the past year have come from colorectal cancer treatment Fusilev, which the company sells in the US, but Teva has a similar, and cheaper, generic injection, and so in the past year the short players have turned their attention to Spectrum, on the assumption that it has no chance against Teva. They ramped up the short position to an annual record of 7 million shares, while the share price rose from a rock-bottom $4 to over $10 at the end of April, just before the FDA meeting to decide whether to approve expanded use of Fuzilev.
Spectrum's share price has jumped in the past year, among other things because contamination was discovered at the Teva plant in the US that produces the generic injection, leading to a temporary shutdown, and a shortage that boosted Spectrum's sales. The short players built their position against the stock on the basis of two assumptions. The first, and more important of the two, was that on April 29, the FDA would not allow expanded use of Fusilev, as had happened a year earlier, sending the stock tumbling. The second was that Teva's plant was due to resume production, and so sales of Spectrum's Fusilev would drop, being similar to but costlier than Teva's.
Thestreet.com biotech reporter Adam Feuerstein had taken a position against investing in Spectrum all year, which made investors suspect him of being connected to the hedge funds that were shorting the stock. The climax came on Monday, May 2, after Spectrum announced that it had obtained the FDA approval for expanding use of the Fusilev injection to advanced metastatic colorectal cancer patients, and that it was gearing up to boost production at the FDA's request, because of the shortage brought about by the continued closure of the Teva plant.
On the back of the positive announcement, Spectrum's share price opened with a 14% leap on May 2, to a record $10.3, but in the course of the session, when the momentum was at its peak, Feuerstein published an article on thestreet.com against the company, claiming that the approval was worthless, since Teva would resume production at any moment, and its injection was similar but cheaper. The damage was done. The stock changed direction and headed south, tumbling to almost $7 within two weeks, and the strong first quarter results released two days after the article was published failed to help.
On their blogs, investors went crazy at the precise timing of Feuerstein's article, at the stock's intraday peak, which, they claimed, played quite fantastically to the short players' benefit. On his personal blog, Feuerstein denies having anything against the company or its CEO, claiming him as old friend. Despite that, he renewed the attack last week, but this time Shrotriya was armed and ready, with ammunition that prevented the stock from collapsing.
The zealous Feuerstein discovered that Teva had reported on a professional website that although the US plant was still being tested, and was not producing in large quantities, at the request of the FDA, which feared a shortage, it was importing large consignments of the injection into the US from Europe. On the basis of that discovery, he came out with another negative article, claiming that Spectrum would be hurt by Teva's imports, and that its advantage was at an end. On a normal day, that would have been enough to undermine the share, but it seems that Shrotriya also saw Teva's report, and knew who would use it against him.
Spectrum anticipated with an announcement of its own, at the end of which it stated that "We expect record second quarter and full-year 2011 revenues." The announcement said, "We are now able to meet the growing needs of the tens of thousands of patients who depend upon FUSILEV's availability. Having multiple US suppliers also reduces the risk of supply interruptions, so physicians who prefer to use FUSILEV in their treatment regimens do not have to seek alternative treatment options," a hint at Teva. Incidentally, as far as Teva is concerned, this is something negligible relative to its sales, and there are those who say that Teva has no interest in promoting its drug, because of its low profitability, but that the company is acting under pressure from the FDA, which fears a shortage.
The point is that I see Spectrum as an attractive stock for anyone looking for a big biotech dream that could come true through the two new drugs it has in development, and that are slated to be submitted for FDA approval next year. They are aimed at very large markets in oncology. But until then, the financial risk is very low, because the company has lots of cash, which is not typical of small companies, and what is more it has the two drugs that are already selling and earning profits, and it is not at all clear how much of a threat Teva really presents to the colorectal cancer treatment.
In my view, this being the case, sooner or later the large short position will lead to the short players being wiped out, which in turn will make the share price soar. In addition, Spectrum's CEO does not deny that the company is a potential takeover target for one of the pharmaceutical giants, and so he has taken care to arrange a bonus for himself if the sale is at a valuation above $750 million, a bonus that will also be paid if the company reaches that market cap without a sale, through a normal rise in the share price thanks to business growth.
Published by Globes [online], Israel business news - www.globes-online.com - on June 30, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
בנוסף אולי יעניין אותך לנסוע במציאות בעולמו של וולט דיסני
Teva liefert wieder..
Was bedeutet das?
17-Jun-2011
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On June 13, 2011, Spectrum Pharmaceuticals, Inc. (the "Company"), entered into an Amendment (the "Amendment") to the License, Development, Supply and Distribution Agreement, dated October 28, 2008, by and among the Company, Allergan Sales, LLC, Allergan USA, Inc. and Allergan, Inc. As previously disclosed, the License, Development, Supply and Distribution Agreement provides for a collaboration between the parties in conducting development and related activities, marketing in certain territories, and selling of product(s) containing Apaziquone for certain indications in those territories all on the terms and conditions set forth in such Agreement. Under the Amendment, among other things, the parties agreed to change the indication for future planned studies from BCG Refractory to Multiple Instillation, to extend certain milestone dates and to modify certain payment obligations and expense allocation provisions.
The foregoing description of Amendment does not purport to be complete and is qualified in its entirety by Amendment, which will be filed as an Exhibit to the Company's Form 10-Q for the quarterly period ended June 30, 2011. The Company intends to submit a FOIA confidential treatment request to the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, requesting that it be permitted to redact certain portions of the Amendment. The omitted material will be included in the request for confidential treatment.
Antwort auf Beitrag Nr.: 41.650.531 von Oberlaendler am 15.06.11 16:34:18Sehr gut!
SPPI hat sich innerhalb von 3 Jahren bemerkenswert gemausert. Was mich am meisten freut ist das Fusilev entgegen vieler Unkenrufe doch ein Erfolg wird. Für mich egal ob daran der Shortage "Schuld" ist und die Gründe dafür. Man könnte ebensogut sagen Rajesh ist ein schlauer Fuchs der das im Vorfeld geahnt hat
SPPI hat sich innerhalb von 3 Jahren bemerkenswert gemausert. Was mich am meisten freut ist das Fusilev entgegen vieler Unkenrufe doch ein Erfolg wird. Für mich egal ob daran der Shortage "Schuld" ist und die Gründe dafür. Man könnte ebensogut sagen Rajesh ist ein schlauer Fuchs der das im Vorfeld geahnt hat
Trading Spotlight
Spectrum Pharmaceuticals Announces Authorization of Stock Repurchase Program up to $25 Million
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that its Board of Directors has authorized the purchase of up to $25 million of its common stock through the end of 2012.
“I am pleased to announce this share repurchase program,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. Dr. Shrotriya added, “Spectrum’s Board of Directors and senior management have confidence in our Company and believe repurchases of Spectrum stock represent an attractive opportunity to enhance long-term shareholder value. Furthermore, we are confident in the projected cash flows from our core products and believe that this will not hamper our ability to continue to fund future growth through our pipeline or other strategic growth opportunities. Spectrum has no current need to raise financing for its daily operations and current research and development programs.”
Stock will be purchased from time to time, in the open market, through block trades, through 10b5-1 plans, or through privately negotiated transactions in compliance with Securities and Exchange Commission guidelines. The Company expects the stock repurchase program to help partially offset potential dilution from outstanding warrants and equity incentive programs. The timing and actual number of shares repurchased will depend on a variety of factors including price, market conditions and corporate and regulatory requirements. Purchases may be made beginning immediately and ending at such time as the authorized funds are spent or the program is discontinued. The program does not obligate Spectrum to acquire any particular amount of common stock, and the program may be modified or suspended at any time at Spectrum’s discretion.
http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
Sieht heute gut aus.
Grüße Oberländler
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that its Board of Directors has authorized the purchase of up to $25 million of its common stock through the end of 2012.
“I am pleased to announce this share repurchase program,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. Dr. Shrotriya added, “Spectrum’s Board of Directors and senior management have confidence in our Company and believe repurchases of Spectrum stock represent an attractive opportunity to enhance long-term shareholder value. Furthermore, we are confident in the projected cash flows from our core products and believe that this will not hamper our ability to continue to fund future growth through our pipeline or other strategic growth opportunities. Spectrum has no current need to raise financing for its daily operations and current research and development programs.”
Stock will be purchased from time to time, in the open market, through block trades, through 10b5-1 plans, or through privately negotiated transactions in compliance with Securities and Exchange Commission guidelines. The Company expects the stock repurchase program to help partially offset potential dilution from outstanding warrants and equity incentive programs. The timing and actual number of shares repurchased will depend on a variety of factors including price, market conditions and corporate and regulatory requirements. Purchases may be made beginning immediately and ending at such time as the authorized funds are spent or the program is discontinued. The program does not obligate Spectrum to acquire any particular amount of common stock, and the program may be modified or suspended at any time at Spectrum’s discretion.
http://www.nasdaq.com/aspx/company-news-story.aspx?storyid=2…
Sieht heute gut aus.
Grüße Oberländler
SEC Filing von gerade eben. Scheint so als pusht er auch kräftig auf der soeben stattfindenden HV:
On June 13, 2011, at the annual stockholders meeting, after highlighting the safe harbor disclosures pertaining to forward looking statements, Rajesh C. Shrotriya, MD, Chairman of the Board, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. (the “Company”) remarked that the Company currently anticipates annual revenues could be in excess of $100 million. As with all forward looking statements, there can be no assurance that such results will be achieved.
On June 13, 2011, at the annual stockholders meeting, after highlighting the safe harbor disclosures pertaining to forward looking statements, Rajesh C. Shrotriya, MD, Chairman of the Board, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. (the “Company”) remarked that the Company currently anticipates annual revenues could be in excess of $100 million. As with all forward looking statements, there can be no assurance that such results will be achieved.
Ich höre mir gerade Jefferies Conference an.
Wichtigste Punkte:
* Raj erwartet > 100Mio USD Fusilev Umsatz in 2011. Zur Erinnerung, Q1 waren es 35 Mio USD. Zukünftig erwartet er in 1-2Jahren > 180-200Mio / Jahr "easily" (Anm. Ville: Was für ein Pusher!)
* Zevalin erwartet er ein langsames Wachstum solange bis Bioscan Removal nicht erreicht, so ca. 10-15% / Jahr.
Wichtigste Punkte:
* Raj erwartet > 100Mio USD Fusilev Umsatz in 2011. Zur Erinnerung, Q1 waren es 35 Mio USD. Zukünftig erwartet er in 1-2Jahren > 180-200Mio / Jahr "easily" (Anm. Ville: Was für ein Pusher!)
* Zevalin erwartet er ein langsames Wachstum solange bis Bioscan Removal nicht erreicht, so ca. 10-15% / Jahr.
Antwort auf Beitrag Nr.: 41.552.031 von Ville7 am 25.05.11 07:36:37Na dann muß Sppi beamen!
Antwort auf Beitrag Nr.: 41.547.939 von Magnetfeldfredy am 24.05.11 13:15:32Wir haben wieder eine Aschewolke, die letztes Jahr die Zevalinverkäufe zum Stillstand brachten, weil das Produkt in Europa hergestellt wird und ohne Transport per Flugzeug siehts mau aus...
Durchsuchen
